tirzepatide surmount-1 percent weight loss 72 weeks Oral tirzepatide: what actually exists, what does not, and what is coming next Tirzepatide after intensive lifestyle intervention

Portion control can feel difficult even with strong effort

Mounjaro Tirzepatide injections are not appropriate for everyone so it is important to discuss the treatment option with your attending physician to make a determination about whether it is right for you

23 May SAHPRA and the SAPC Crack Down on Unlawful Manufacturing of Unregistered GLP-1/ GIP Medicines Pretoria, 23 May 2026 The South African Health Products Regulatory Authority (SAHPRA), in collaboration with the South African Pharmacy Council (SAPC), has intensified enforcement action against the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines containing either Semaglutide, Tirzepatide, or a combination product containing both Semaglutide and Tirzepatide promoted for weight loss

Keywords: Obesity/overweight, Tirzepatide, Type 2 diabetes Key Summary Points Introduction Tirzepatide is a long-acting glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (GIPRA) and glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA)

Never inject into areas displaying redness, warmth, swelling, or hardness, as these signs indicate inflammation from previous injections and injecting there may worsen tissue damage

Take home message Mounjaros ability to reduce alcohol consumption represents an unexpected but significant benefit for many people